Business
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation New non-human primate data projects a human half-life of up to 100 days, potentially enabling treatment with only twice-yearly dosing Extended half-life data and differentiated mechanism of action reinforce IBIO-610’s potential as a leading next-generation therapy for obesity and cardiometabol
About this update from Ibio, Inc.
[{"type":"image","alt":"iBio, Inc.","displaySize":"","headline":null,"caption":"iBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":170,"url":"https://media.zenfs.com/en/globenewswire.com/7b73f55b88269d5e23378e624b0ffcac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SJdaoYV8WWMD9fxupwqycw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7b73f55b88269d5e23378e624b0ffcac","width":300,"height":170}},"lazy":false},{"type":"text","content":"Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation","length":205,"tagName":"p"},{"type":"text","content":"New non-human primate data projects a human half-life of up to 100 days, potentially enabling treatment with only twice-yearly dosing","length":133,"tagName":"p"},{"type":"text","content":"Extended half-life data and differentiated mechanism of action reinforce IBIO-610’s potential as a leading next-generation therapy for obesity and cardiometabolic disease","length":170,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data. The new data demonstrates an extended half-life of 33.2 days in NHPs and a predicted human half-life of up to 100 days, suggesting the potential for dosing as infrequently as twice per year. The findings will be presented by Cory Schwartz, Ph.D., Director of Research and Early Development of iBio, during an oral session at ObesityWeek® 2025, taking place November 4–7 in Atlanta.","length":702,"tagName":"p"},{"type":"text","content":"“GLP-1 therapies have transformed the treatment for obesity, but gaps in patient care remain for durable options addressing biology beyond appetite control,” said Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio. “Our AI-enabled discovery platform has accomplished what was long considered extremely difficult - creating potentially a first-in-class long-acting antibody against Activi...